Media Centre
Browse through the latest LEO Pharma press releases and articles, and see what people are talking about on social media.
LEO Pharma launches first North American Innovation Lab in Toronto.
- 18-10-2021 Health Canada approves ADTRALZA® (tralokinumab) for the treatment of adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis
- 18-10-2021 Health Canada approves ADTRALZA® (tralokinumab) as a treatment for adults with moderate-to-severe atopic dermatitis
- 04-10-2021 The Product Monograph for Protopic® has been updated
- 20-11-2019 LEO Pharma launches Open Innovation program and partnership with the University of Victoria in Canada
- 07-12-2016 Results of study of low molecular weight heparin in patients with venous thromboembolism (VTE) and severe renal impairment
- 02-11-2016 A global expert panel develops an action plan to increase CAT awareness with the support of LEO Pharma
- 17-10-2016 LEO Pharma helps patients to be #PsoInControl and get the confidence to take better manage their psoriasis
- 03-10-2016 LEO Pharma and Thrombosis Canada join forces to support Clots Matter
- 29-09-2016 New data presented at EADV show skin clearance with Enstilar® improves quality of life
- 01-09-2016 ‘Mountain or Mole Hill?’ Public Skin Cancer Forum in Nanaimo, B.C.
- 01-07-2016 LEO Pharma enters biologics through strategic partnership with AstraZeneca
- 19-03-2016 LEO Pharma Receives Scientific Approval of Enstilar® for the Treatment of Psoriasis in EU
- 07-03-2016 New Preclinical Data for Calcipotriol/betamethasone dipropionate (0,005%/0,05%)
- 18-01-2016 LEO Pharma launches new innovation lab in Canada